Add to ORKGIn-vitro inhalation performance for formoterol dry powder and metred dose inhalers In-vitro characteristics of the emitted dose from the formoterol dry powder and metred dose inhalers to identify the influence of inhalation flow, inhalation volume and the number of inhalation per dos
Background: Spiromax\uae is a novel dry powder inhaler for patients with asthma or chronic obstructi...
A test inhaler with exchangeable air flow resistances encompassing the range of commercial DPIs has ...
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of eff...
Currently available dry powder inhalers (DPIs) for drug delivery to the lungs require turbulent ener...
Three commercial dry powder inhalers with completely different dosing and powder disintegration prin...
European and United States Pharmacopoeia compendial procedures for assessing the in vitro emitted do...
The inhaler device is as important as the powder formulation for the successful development of dry p...
AbstractThe fraction of the emitted dose from an inhaler that has the potential to be deposited into...
Background: Easyhaler device-metered dry powder inhaler containing budesonide and formoterol fumara...
The inhaler device is as important as the powder formulation for the successful development of dry p...
The efficacy of dry powder inhalers (DPIs) is usually related to peak inspiratory flow rate (PIFR) t...
The aerodynamic characteristics of the dose emitted from a dry powder inhaler (DPI) are inhalation f...
Rationale: Efficacy of inhalation therapy is dependent on device performance and drug choice. To rea...
AbstractUsing a proprietary technology known as the X-ACTTM system—Active-metering, Cyclone-separato...
The inhaler device is as important as the powder formulation for the successful development of dry p...
Background: Spiromax\uae is a novel dry powder inhaler for patients with asthma or chronic obstructi...
A test inhaler with exchangeable air flow resistances encompassing the range of commercial DPIs has ...
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of eff...
Currently available dry powder inhalers (DPIs) for drug delivery to the lungs require turbulent ener...
Three commercial dry powder inhalers with completely different dosing and powder disintegration prin...
European and United States Pharmacopoeia compendial procedures for assessing the in vitro emitted do...
The inhaler device is as important as the powder formulation for the successful development of dry p...
AbstractThe fraction of the emitted dose from an inhaler that has the potential to be deposited into...
Background: Easyhaler device-metered dry powder inhaler containing budesonide and formoterol fumara...
The inhaler device is as important as the powder formulation for the successful development of dry p...
The efficacy of dry powder inhalers (DPIs) is usually related to peak inspiratory flow rate (PIFR) t...
The aerodynamic characteristics of the dose emitted from a dry powder inhaler (DPI) are inhalation f...
Rationale: Efficacy of inhalation therapy is dependent on device performance and drug choice. To rea...
AbstractUsing a proprietary technology known as the X-ACTTM system—Active-metering, Cyclone-separato...
The inhaler device is as important as the powder formulation for the successful development of dry p...
Background: Spiromax\uae is a novel dry powder inhaler for patients with asthma or chronic obstructi...
A test inhaler with exchangeable air flow resistances encompassing the range of commercial DPIs has ...
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of eff...